Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.39 |
| ▸ | CCR5 | P51681 | 1/20 | 0.39 |
| ▸ | CCR8 | P51685 | 1/20 | 0.39 |
| ▸ | PBK | Q96KB5 | 11/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 2/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3948904 | 0.77 | PDK2 (0.37) | PBKALDH1A1POLBMAPTHPGD | |
| SCHEMBL1917392 | 0.76 | ADORA3 (0.39) | PBKALDH1A1POLBMAPTHPGD | |
| SCHEMBL1917418 | 0.76 | BRD4 (0.44) | CCR1CCR5CCR8PBKALDH1A1 | |
| SCHEMBL12963909 | 0.76 | ADORA1 (0.38) | PBKALDH1A1POLBMAPTHPGD | |
| SCHEMBL3949234 | 0.75 | TSPO (0.38) | PBKALDH1A1POLBMAPTHPGD | |
| SCHEMBL4149204 | 0.75 | KDM5B (0.48) | PBKPARP1 | |
| SCHEMBL3949386 | 0.74 | BRD4 (0.40) | PDK2PDK4BRD4ADORA3ADORA2A | |
| SCHEMBL3952234 | 0.74 | ADORA3 (0.36) | ALDH1A1POLBMAPTHPGDTSHR | |
| SCHEMBL3952077 | 0.74 | MAPT (0.38) | PBKALDH1A1POLBMAPTHPGD | |
| SCHEMBL30633389 | 0.74 | ADORA3 (0.39) | ADORA3ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2233493-A1 | Macrolides | Pfizer Products Inc. (US) | 2010-09-29 | — | — | EP | disclosed |
| EP-1836211-B1 | MACROLIDES | PFIZER PROD INC (US) | 2010-03-03 | — | — | EP | disclosed |
| US-7462600-B2 | Macrolides | PFIZER INC (US) | 2008-12-09 | — | — | US | disclosed |
| US-20060135447-A1 | Macrolides | CHUPAK LOUIS S | 2006-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135447-A1 | Macrolides | LCAT, NOP2, HDAC6 | CCR1 1678/4885CCR5 1293/4885CCR8 1342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.